Literature DB >> 20668938

p53 status and its prognostic role in extrahepatic bile duct cancer: a meta-analysis of published studies.

Juan Wang1, Xuefeng Wang, Shuyang Xie, Zhonghai Yan, Zunling Li, Youjie Li, Lei Wang, Fei Jiao.   

Abstract

The dysfunction of p53 is the most common genetic alteration in human cancer. A variety of studies have investigated the clinicopathologic correlation of p53 and its impact on patient survival in different types of cancer. For extrahepatic bile duct cancer (EBDC), however, the results were limited and conflicting. In this study, we performed an investigation to confirm whether there was a correlation between p53 status and some routine parameters. To further observe the impact of p53 on the survival of EBDC patients, a meta-analysis based on published studies was conducted. Candidate studies were searched from PubMed, EMBASE, and ISI Web of Science. Our results demonstrated that there were significant correlations between p53 expression and some clinicopathological parameters. Furthermore, the pooled results of the meta-analysis showed that the combined hazard ratio (HR) estimate for overall survival (OS) was 1.53 (95% CI, 1.10-2.14) and 1.23 (95% CI, 0.93-1.75) in univariate and multivariate analysis, respectively. In conclusion, the high level of p53 appears to be an effective prognostic factor to OS of EBDC patients. However, some limitations unavoidable in this meta-analysis and problems of previous p53 studies in EBDC mean that further studies are necessary before significant conclusions can be made.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20668938     DOI: 10.1007/s10620-010-1352-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  48 in total

1.  Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts.

Authors:  J Albores-Saavedra; L Murakata; J E Krueger; D E Henson
Journal:  Cancer       Date:  2000-08-01       Impact factor: 6.860

Review 2.  The p53 family in differentiation and tumorigenesis.

Authors:  Thorsten Stiewe
Journal:  Nat Rev Cancer       Date:  2007-02-01       Impact factor: 60.716

3.  Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.

Authors:  Karel Caca; Jürgen Feisthammel; Karen Klee; Andrea Tannapfel; Helmut Witzigmann; Christian Wittekind; Joachim Mössner; Frieder Berr
Journal:  Int J Cancer       Date:  2002-02-01       Impact factor: 7.396

4.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

5.  Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases.

Authors:  Mai P Hoang; Linda A Murakata; Nora Katabi; Donald E Henson; Jorge Albores-Saavedra
Journal:  Mod Pathol       Date:  2002-12       Impact factor: 7.842

6.  Carcinoma of the ampulla of Vater associated with or without adenoma: a clinicopathologic analysis of 198 cases with reference to p53 and Ki-67 immunohistochemical expressions.

Authors:  M Takashima; T Ueki; E Nagai; T Yao; K Yamaguchi; M Tanaka; M Tsuneyoshi
Journal:  Mod Pathol       Date:  2000-12       Impact factor: 7.842

Review 7.  Post-translational modification of p53 in tumorigenesis.

Authors:  Ann M Bode; Zigang Dong
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

8.  Selective reporting biases in cancer prognostic factor studies.

Authors:  Panayiotis A Kyzas; Konstantinos T Loizou; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

Review 9.  Diagnosis and management of cholangiocarcinoma.

Authors:  Dalbir S Sandhu; Lewis R Roberts
Journal:  Curr Gastroenterol Rep       Date:  2008-02

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  9 in total

1.  The prognostic significance of p53 expression in gastric cancer: a meta-analysis.

Authors:  Kongkong Wei; Lei Jiang; Yaoyao Wei; Yufeng Wang; Xuankun Qian; Qiang Dai; Quanlin Guan
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-15       Impact factor: 4.553

Review 2.  Cholangiocarcinoma: from molecular biology to treatment.

Authors:  Ana F Brito; Ana M Abrantes; João C Encarnação; José G Tralhão; Maria F Botelho
Journal:  Med Oncol       Date:  2015-10-01       Impact factor: 3.064

Review 3.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

Review 4.  An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.

Authors:  Pattaya Seeree; Phorutai Pearngam; Supeecha Kumkate; Tavan Janvilisri
Journal:  Int J Genomics       Date:  2015-09-02       Impact factor: 2.326

5.  Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers.

Authors:  Junko Umeda; Takao Itoi; Atsushi Sofuni; Fumihide Itokawa; Toshio Kurihara; Takayoshi Tsuchiya; Kentaro Ishii; Shujiro Tsuji; Nobuhito Ikeuchi; Reina Tanaka; Ryosuke Tonozuka; Mitsuyoshi Honjo; Shuntaro Mukai; Toshitaka Nagao; Hisashi Oshiro; Fuminori Moriyasu
Journal:  J Oncol       Date:  2013-12-18       Impact factor: 4.375

Review 6.  ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.

Authors:  Shankun Zhao; Youwen Xu; Weizhou Wu; Pan Wang; Yichao Wang; Hao Jiang; Jie Zhu
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

7.  ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma.

Authors:  Kyun Woo Park; Eun-Seon Jung; Dong-Gu Kim; Young-Kyung Yoo; Tae-Ho Hong; In Seok Lee; Yoon Ho Koh; Ji-Hoon Kim; Myung Ah Lee
Journal:  Cancer Res Treat       Date:  2013-03-31       Impact factor: 4.679

8.  Radiotherapy prolongs biliary metal stent patency in malignant pancreatobiliary obstructions.

Authors:  Semi Park; Jeong Youp Park; Seungmin Bang; Seung Woo Park; Jae Bock Chung; Si Young Song
Journal:  Gut Liver       Date:  2013-06-11       Impact factor: 4.519

9.  Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing Cholangitis.

Authors:  Margriet R Timmer; Chiu T Lau; Sybren L Meijer; Paul Fockens; Erik A J Rauws; Cyriel Y Ponsioen; Silvia Calpe; Kausilia K Krishnadath
Journal:  Gastroenterol Res Pract       Date:  2016-04-03       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.